Evolution of insulin: From human to analog

American Journal of Medicine

Volumn 127, Issue 10, 2014, Pages S25-S38

  Tibaldi, Joseph M ^a  

^a Queens Diabetes and Endocrinology   (United States)

Author keywords

Analog insulin; Human insulin; Hypoglycemia; Insulin evolution; Type 2 diabetes

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN TREATMENT; LIFE EXPECTANCY; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; WEIGHT CHANGE; WEIGHT GAIN; ANALOGS AND DERIVATIVES; ANALYSIS; CHEMICALLY INDUCED; CLASSIFICATION; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; PROCEDURES; PSYCHOLOGY;

BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; QUALITY OF LIFE; WEIGHT GAIN;

EID: 84921709085     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.07.005     Document Type: Article

References (78)

1. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
2. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care. 2006;29:1269-1274.
3. Raslova K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract. 2004;66:193-201,
4. Erratum in Diabetes Res Clin Pract. 2006;72:112.
5. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130-1136.
6. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes - causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799-812.
7. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648-659.
8. Vora J, Heise T. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review. Diabetes Obes Metab. 2013;15:701-712.
9. Felig P. Landmark perspective: Protamine insulin. Hagedorn's pioneering contribution to drug delivery in the management of diabetes. JAMA. 1984;251:393-396.
10. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
11. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443-445.
12. Havelund S, Plum A, Ribel U, et al. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498-1504.
13. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104-2114.
14. Sorli C. New developments in insulin therapy for type 2 diabetes. Am J Med. 2014;127(Suppl 1):S39-S48.
15. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614-1620.
16. Luzio S, Dunseath G, Peter R, et al. Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes. Diabetologia. 2006;49: 1163-1168.
17. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107-1112.
18. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290-299.
19. Heise T, Nosek L, Bottcher SG, et al. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-950.
20. Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes. 2011;60(Suppl 1A):LB12.
21. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859-864.
22. Sanofi-aventis USA. Last updated 2013. Lantus Prescribing Information. Available at: http://products.sanofi.us/lantus/lantus.html. Accessed August 8, 2014.
23. Novo Nordisk A/S. Last updated 2013. Detemir Prescribing Information. Available at: http://www.novo-pi.com/levemir.pdf. Accessed August 8, 2014.
24. Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulinnaive people with type 2 diabetes. Diabetologia. 2008;51:408-416.
25. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab. 2005;7:56-64.
26. Raskin P, Gylvin T, Weng W, Chaykin L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev. 2009;25:542-548.
27. Hollander P, Cooper J, Bregnhoj J, Pedersen CB. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther. 2008;30:1976-1987.
28. Swinnen SG, Simon AC, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011:CD006383.
29. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-2471.
30. Onishi Y, Iwamoto Y, Yoo SJ, et al. Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Invest. 2013;4:605-612.
31. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-totarget non-inferiority trial. Lancet. 2012;379:1498-1507.
32. Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes. Diabetes Care. 2013;36: 858-864.
33. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab. 2007;9:31-38.
34. Dornhorst A, Luddeke HJ, Sreenan S, et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohort. Int J Clin Pract. 2007;61:523-528.
35. Hansen BF, Glendorf T, Hegelund AC, et al. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10. PLoS One. 2012;7:e34274.
36. Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause celebre? Int J Clin Pract. 2010;64:628-636.
37. Gough SC, Belda-Iniesta C, Poole C, et al. Insulin therapy in diabetes and cancer risk: current understanding and implications for future study: proceedings from a meeting of a European Insulin Safety Consensus Panel, convened and sponsored by Novo Nordisk, held Tuesday October 5, 2010 at The Radisson Edwardian Heathrow Hotel, Hayes, Middlesex, UK. Adv Ther. 2011;28(Suppl 5):1-18.
38. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia . 2009;52:1732-1744.
39. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328.
40. Bolli GB, Hahn AD, Schmidt R, et al. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012;35:2626-2630.
41. Nishimura E, Sorensen AR, Hansen BF, et al. Insulin degludec, a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimising mitogenic potential. Diabetologia. 2010;53(Suppl 1):S388-S389.
42. Moghissi E, King AB. Individualizing insulin therapy in the management of type 2 diabetes. Am J Med. 2014;127(Suppl 1):S3-S10.
43. Bolli GB, Luzio S, Marzotti S, et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metab. 2011;13:251-257.
44. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577-1596.
45. Home PD. The pharmacokinetics and pharmacodynamics of rapidacting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14:780-788.
46. Luzio S, Peter R, Dunseath GJ, et al. A comparison of preprandial insulin glulisine versus insulin lispro in people with type 2 diabetes over a 12-h period. Diabetes Res Clin Pract . 2008;79: 269-275.
47. Heinemann L, Kapitza C, Starke AA, Heise T. Time-action profile of the insulin analogue B28Asp. Diabet Med. 1996;13:683-684.
48. Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care. 1998;21:1910-1914.
49. Mudaliar SR, Lindberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care. 1999;22:1501-1506.
50. Heise T, Nosek L, Spitzer H, et al. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab. 2007;9: 746-753.
51. von Mach MA, Brinkmann C, Hansen T, et al. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2002;110: 416-419.
52. Lindholm A, McEwen J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care. 1999;22:801-805.
53. Rave K, Klein O, Frick AD, Becker RH. Advantage of premealinjected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care. 2006;29:1812-1817.
54. Heinemann L, Heise T, Wahl LC, et al. Prandial glycaemia after a carbohydrate-rich meal in type I diabetic patients: using the rapid acting insulin analogue [Lys(B28), Pro(B29)] human insulin. Diabet Med. 1996;13:625-629.
55. Rosenfalck AM, Thorsby P, Kjems L, et al. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol. 2000;37:41-46.
56. Holmes G, Galitz L, Hu P, Lyness W. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment. Br J Clin Pharmacol. 2005;60:469-476.
57. Lilly USA. Humalog Mix 75/25 Prescribing Information. Available at: http://pi.lilly.com/us/humalog7525-pi.pdf. Accessed August 8, 2014.
58. Sanofi-aventis USA. Apidra Prescribing Information. Available at: http://products.sanofi.us/apidra/apidra.pdf. Accessed August 8, 2014.
59. Novo Nordisk A/S. NovoRapid Product Information. Available at http://www.novonordisk.com.au/media/PIs/NovoRapid-NovoMix-PI3a.pdf. Accessed August 8, 2014.
60. Bretzel RG, Arnolds S, Medding J, Linn T. A direct efficacy and safety comparison of insulin aspart, human soluble insulin, and human premix insulin (70/30) in patients with type 2 diabetes. Diabetes Care. 2004;27:1023-1027.
61. Dailey G, Rosenstock J, Moses RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care. 2004;27:2363-2368.
62. Ross SA, Zinman B, Campos RV, Strack T. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med. 2001;24:292-298.
63. Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009;11:53-59.
64. Heller S, Bode B, Kozlovski P, Svendsen AL. Meta-analysis of insulin aspart versus regular human insulin used in a basal-bolus regimen for the treatment of diabetes mellitus. J Diabetes. 2013;5: 482-491.
65. Rys P, Pankiewicz O, Lach K, et al. Efficacy and safety comparison of rapid-acting insulin aspart and regular human insulin in the treatment of type 1 and type 2 diabetes mellitus: a systematic review. Diabetes Metab. 2011;37:190-200.
66. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev. 2006:CD003287.
67. Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ. 2009;180:385-397.
68. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49:999-1005.
69. Stammberger I, Seipke G, Bartels T. Insulin glulisineea comprehensive preclinical evaluation. Int J Toxicol. 2006;25:25-33.
70. Liebl A, Prusty V, Valensi P, et al. Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings. Drugs. 2012;72:1495-1520.
71. Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol. 2000;56:399-403.
72. Weyer C, Heise T, Heinemann L. Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care . 1997;20: 1612-1614.
73. Hermansen K, Colombo M, Storgaard H, et al. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care. 2002;25:883-888.
74. Novo Nordisk A/S. Last updated 2013. NovoLog Mix Prescribing Information. Available at: http://www.novonordisk-us.com/Images/ PDF/Novolog-Jun-29-2011.pdf. Accessed August 8, 2014.
75. Qayyum R, Wilson LM, Bolen S, et al. Last updated 2008. Comparative effectiveness, safety, and indications of insulin analogues in premixed formulations for adults with type 2 diabetes. Comparative Effectiveness Review No. 14. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. 290-02-0018.) Rockville, MD: Agency for Healthcare Research and Quality. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed August 8, 2014.
76. Davidson JA, Liebl A, Christiansen JS, et al. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a metaanalysis. Clin Ther. 2009;31:1641-1651.
77. Niskanen L, Jensen LE, Rastam J, et al. Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. Clin Ther. 2004;26:531-540.
78. Vaag A, Lund SS. Insulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analogues. Eur J Endocrinol. 2012;166:159-170.